Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EchoIQ Limited ( (AU:EIQ) ) has provided an update.
Echo IQ Limited has presented compelling data at the AHA Scientific Sessions 2025, highlighting the potential of its AI-powered tool, EchoSolv AS, to enhance the diagnosis and management of severe aortic stenosis (AS). The studies demonstrated that EchoSolv AS outperformed traditional cardiologist methods, particularly in identifying severe AS in women, and improved gender equity in diagnosis. This advancement could significantly impact patient outcomes by reducing delays in diagnosis and treatment, thereby positioning Echo IQ as a leader in AI-driven medical solutions.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
More about EchoIQ Limited
Echo IQ Limited is an AI and medical technology company focused on improving healthcare outcomes through advanced analytics and artificial intelligence solutions. The company specializes in developing tools for better diagnosis and monitoring of cardiovascular conditions, with a particular emphasis on addressing gaps in standard care practices.
Average Trading Volume: 1,457,056
Technical Sentiment Signal: Hold
Current Market Cap: A$126.8M
See more insights into EIQ stock on TipRanks’ Stock Analysis page.